Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168:1159–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Acelajado MC, Hughes ZH, Oparil S, Calhoun DA. Treatment of resistant and refractory hypertension. Circ Res. 2019;124:1061–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N. Engl J Med. 2023;388:395–405.

Article  CAS  PubMed  Google Scholar 

Szabo Yamashita T, Shariq OA, Foster TR, Lyden ML, Dy BM, Young WF Jr, et al. Unilateral adrenalectomy for primary aldosteronism due to bilateral adrenal disease can result in resolution of hypokalemia and amelioration of hypertension. World J Surg. 2023;47:314–8.

Article  PubMed  Google Scholar 

Zhou Y, Wang D, Liu Q, Hou J, Wang P. Case report: percutaneous adrenal arterial embolization cures resistant hypertension. Front Cardiovasc Med. 2022;9:1013426.

Article  PubMed  PubMed Central  Google Scholar 

Zhao Z, Liu X, Zhang H, Li Q, He H, Yan Z, et al. Catheter-based adrenal ablation remits primary aldosteronism: a randomized medication-controlled trial. Circulation. 2021;144:580–2.

Article  PubMed  Google Scholar 

Zhang H, Li Q, Liu X, Zhao Z, He H, Sun F, et al. Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: an efficacy and safety, proof-of-principle trial. J Clin Hypertens. 2020;22:1618–26.

Article  Google Scholar 

Zhou Y, Liu Q, Wang X, Wan J, Liu S, Luo T, et al. Adrenal ablation versus mineralocorticoid receptor antagonism for the treatment of primary aldosteronism: a single-center prospective cohort study. Am J Hypertens. 2022;35:1014–23.

Article  CAS  PubMed  Google Scholar 

Wexler BC, McMurtry JP. Differences in adrenal cholesterol, ascorbic acid, circulating corticosterone and aldosterone during the onset of hypertension in SHR vs WKy rats. Cardiovasc Res. 1982;16:573–9.

Article  CAS  PubMed  Google Scholar 

Kenyon CJ, DeConti GA, Cupolo NA, Morris DJ. The role of aldosterone in the development of hypertension in spontaneously hypertensive rats. Endocrinology. 1981;109:1841–5.

Article  CAS  PubMed  Google Scholar 

Stern N, Beck FJ, Eggena P, Phillips D, Sowers JR. Corticosteroid modulation of the renin system and blood pressure in the spontaneously hypertensive rat. Clin Exp Hypertens A. 1983;5:1543–57.

CAS  PubMed  Google Scholar 

Bucher B, Stoclet JC. Adrenomedullary and beta-adrenergic participation in enhanced sympathetic pressor responses of spontaneously hypertensive rats. Eur J Pharm. 1987;138:233–8.

Article  CAS  Google Scholar 

Chun TY, Chander PN, Kim JW, Pratt JH, Stier CT Jr. Aldosterone, but not angiotensin II, increases profibrotic factors in kidney of adrenalectomized stroke-prone spontaneously hypertensive rats. Am J Physiol Endocrinol Metab. 2008;295:E305–12.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chander PN, Rocha R, Ranaudo J, Singh G, Zuckerman A, Stier CT Jr. Aldosterone plays a pivotal role in the pathogenesis of thrombotic microangiopathy in SHRSP. J Am Soc Nephrol. 2003;14:1990–7.

Article  CAS  PubMed  Google Scholar 

Wang X, Luo T, Yang Y, Zhou Y, Hou J, Wang P. Unilateral chemical ablation of the adrenal gland lowers blood pressure and alleviates target organ damage in spontaneously hypertensive rats. Hypertens Res. 2023; https://doi.org/10.1038/s41440-023-01444-2.